GlassScriptPhysician profile
Jaime E Whitlow
NPI 1184863771
$7,003.06
in general payments reported to CMS, 2019-2025
49 companies · $900 in 2025
The $900 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,661 · 2022: $1,456 · 2023: $1,580 · 2024: $1,406 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,886.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,493.54 | 2021-2025 | |
| Novo Nordisk INC | $843.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $594.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $386.96 | 2021-2025 | Farxiga, Breztri, Tezspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.57 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $258.47 | 2021-2025 | Repatha, Otezla, Evenity |
| Genzyme Corporation | $249.71 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $235.26 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $191.56 | 2021-2025 | Rexulti, Jynarque |
| Janssen Pharmaceuticals, INC | $147.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $129.95 | 2021-2022 | |
| Biogen, INC. | $127.52 | 2021 | |
| Glaxosmithkline, LLC. | $127.22 | 2021-2023 | Nucala, Shingrix, Arexvy |
| Exact Sciences Corporation | $125.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $119.99 | 2022 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $112.82 | 2021 | |
| Merck Sharp & Dohme LLC | $112.76 | 2021-2025 | Vaxneuvance, Capvaxive, Vaxelis |
| Lilly USA, LLC | $109.43 | 2022-2025 | Mounjaro, Emgality, Reyvow |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.12 | 2021-2023 | Jardiance |
| Vanda Pharmaceuticals INC. | $91.70 | 2024-2025 | Hetlioz, Fanapt |
| Mylan Specialty L.P. | $90.03 | 2021-2024 | Yupelri |
| Neurocrine Biosciences, INC. | $79.90 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $77.58 | 2021-2025 | Austedo Xr, Ajovy |
| Eisai INC. | $68.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $66.29 | 2021-2023 | |
| Neurelis, INC. | $58.55 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.10 | 2024-2025 | Eliquis, Cobenfy |
| Sunovion Pharmaceuticals INC. | $54.74 | 2021 | |
| Abbott Laboratories | $54.17 | 2021-2023 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.69 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $47.91 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $47.44 | 2021 | |
| Aimmune Therapeutics, INC. | $46.96 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $36.60 | 2021-2023 | Myrbetriq |
| Lundbeck LLC | $35.36 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $32.35 | 2021-2022 | |
| Amarin Pharma, INC. | $31.92 | 2021 | |
| Dexcom, INC. | $28.55 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $27.87 | 2023-2024 | Flucelvax, Fluad, Fluad Quadrivalent |
| Nestle Healthcare Nutrition INC. | $24.14 | 2021 | |
| Inspire Medical Systems, INC. | $22.04 | 2025 | Inspire |
| Gilead Sciences, INC. | $21.98 | 2024 | |
| Tactile Systems Technology INC | $20.60 | 2024 | Entre Plus, Flexitouch Plus |
| Electromed, INC. | $17.41 | 2024 | Smartvest |
| Alkermes, INC. | $17.09 | 2024 | Vivitrol |
| Verona Pharma, INC. | $16.40 | 2025 | Ohtuvayre |
| Inogen, INC. | $15.70 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.33 | 2024 | Voquezna |
| Ani Pharmaceuticals, INC. | $13.85 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Whitlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.